{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020535","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.167086+00:00","generated_at":"2026-06-22T21:50:56.573254+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galecto GB1211 reduces signs of liver impairment in GULLIVER-2 trial; data presented at AASLD","bullets":["GB1211 well-tolerated with predictable PK; showed reductions in liver enzymes and FibroScan, indicating decreased inflammation and steatosis.","Part 2 data selected as 'Best of The Liver Meeting' in NASH/NAFLD category.","Preclinical rabbit model: GB1211 significantly reduced inflammation, fibrosis, and fat vs control.","Galecto to host webinar Nov 8, 2022 at 8:00 AM ET to discuss expanded topline data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020535","json":"https://secwatch.observer/filing/0000950170-22-020535.json","markdown":"https://secwatch.observer/filing/0000950170-22-020535.md","text":"https://secwatch.observer/filing/0000950170-22-020535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017022020535/0000950170-22-020535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017022020535/glto-20221031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:50:56.573254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}